GlassScriptPhysician profile
Melissa A Borkowski
NPI 1487605473
$4,261.90
in general payments reported to CMS, 2019-2025
48 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.38 · 2023: $1,464 · 2024: $1,366 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.53 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.90 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Janssen Biotech, INC. | $332.93 | 2023-2025 | Erleada, Tecvayli, Darzalex |
| Jazz Pharmaceuticals INC. | $253.36 | 2023-2025 | |
| Celgene Corporation | $212.15 | 2023-2025 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $168.18 | 2023-2025 | Alunbrig, Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $147.06 | 2024-2025 | |
| Genzyme Corporation | $135.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.21 | 2024-2025 | Opdivo, Krazati |
| Seagen INC. | $124.71 | 2023-2025 | Adcetris, Padcev |
| Novo Nordisk INC | $123.80 | 2023 | |
| Myriad Genetic Laboratories, INC. | $123.25 | 2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $122.36 | 2024-2025 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $120.88 | 2023-2025 | Retevmo, Jaypirca, Verzenio |
| G1 Therapeutics, INC. | $112.82 | 2023 | Cosela |
| Emd Serono, INC. | $112.06 | 2023-2025 | Bavencio |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $103.14 | 2023-2025 | Padcev, Xospata, Xtandi |
| Pfizer INC. | $84.40 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $84.10 | 2024-2025 | Xpovio |
| Genmab U.S., INC. | $82.73 | 2023-2025 | Epkinly |
| Sobi, INC | $80.06 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $71.52 | 2024-2025 | Monoferric, Cosela |
| Daiichi Sankyo INC. | $65.97 | 2023-2024 | Enhertu |
| Taiho Oncology, INC. | $65.66 | 2024-2025 | |
| Eisai INC. | $62.22 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $59.39 | 2023-2025 | Pyrukynd |
| Abbvie INC. | $55.40 | 2023-2025 | |
| Exelixis INC. | $53.79 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $52.91 | 2023-2025 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $52.09 | 2023-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $50.42 | 2023-2024 | |
| Blueprint Medicines Corporation | $45.90 | 2023 | Ayvakit |
| Legend Biotech USA INC. | $45.35 | 2024-2025 | Carvykti |
| Glaxosmithkline, LLC. | $44.87 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $43.38 | 2023 | Blincyto, Vectibix, Xgeva |
| Octapharma USA, INC. | $41.56 | 2024-2025 | Octagam Immune Globulin (Human) |
| Stemline Therapeutics INC. | $40.02 | 2023 | Orserdu |
| Incyte Corporation | $37.59 | 2023-2025 | Monjuvi, Jakafi |
| Mirati Therapeutics, INC. | $37.34 | 2024 | Krazati |
| Adaptive Biotechnologies Corporation | $36.33 | 2024-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $32.06 | 2023-2024 | Fotivda |
| Edwards Lifesciences Corporation | $27.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.78 | 2023 | |
| Rigel Pharmaceuticals, INC. | $25.27 | 2024 | Tavalisse, Rezlidhia |
| Tempus Ai, INC | $24.52 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.25 | 2025 | |
| Kyowa Kirin, INC. | $17.97 | 2023 | Poteligeo |
| Morphosys, US INC. | $16.01 | 2023 | Monjuvi |
| Novocure INC. | $15.53 | 2025 | Optune Gio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Borkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.